<DOC>
	<DOCNO>NCT02943681</DOCNO>
	<brief_summary>This study evaluate non-specific effect child mortality morbidity second dose measles second year life . Half study participant receive second dose measles vaccine 18 month age half receive second dose measles 4 year age end study .</brief_summary>
	<brief_title>A Second Dose Measles Vaccine ( MV ) Second Year Life</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children need receive third dose inactivated vaccine ( Penta , PCV13 IPV ) measles vaccination . Having severe malformation impair health Having receive second dose measles vaccine Severely ill ( require hospitalization ) upon clinical examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>